Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trialDaniel V.T. Catenacci, Yung‐Jue Bang, Haeseong Park et al.|The Lancet Oncology|2020Cited by 190
Potent antitumor activity of cabozantinib, a c‐<scp>MET</scp> and <scp>VEGFR</scp>2 inhibitor, in a colorectal cancer patient‐derived tumor explant modelEun‐Kee Song, John J. Arcaroli|International Journal of Cancer|2014Cited by 61